Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant CancersHusain Yar Khan, Asfar S. Azmi, Philip A. Philip et al.|Cancer Research Communications|2022Cited by 27
Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancersHusain Yar Khan, Asfar S. Azmi, Misako Nagasaka et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1
Supplementary Figures 1-4, Tables 1-2 from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant CancersHusain Yar Khan, Asfar S. Azmi, Misako Nagasaka et al.|Unknown|2023Cited by 0
Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant CancersHusain Yar Khan, Asfar S. Azmi, Misako Nagasaka et al.|Unknown|2023Cited by 0
Supplementary Figures 1-4, Tables 1-2 from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant CancersHusain Yar Khan, Asfar S. Azmi, Misako Nagasaka et al.|Unknown|2023Cited by 0